Rainer Boehm joins Nordic Nanovector Board of Directors
Nordic Nanovector ASA today announces that Rainer Boehm, MD was elected as a member of its Board of Directors at the companys Annual General Meeting on 30 May 2018.
Mr Boehm is an oncology expert with nearly 30 years product development, commercial and corporate development experience working at Novartis, where since 2014 he has held the role of Chief Commercial & Medical Affairs Officer of Novartis Pharma (Switzerland). He has also held various other senior roles regionally and globally within the Oncology and Pharmaceutical divisions, including Executive Vice President, North America of Novartis Oncology in the US from 2005-2010.
During his tenure at Novartis, Mr Boehm oversaw the commercial launches of various oncology brands in the US and globally including Femara, Zometa, Glivec, among others. Mr Boehm is a member of the Board of Directors at Cellectis SA and Humanigen Inc.
He has a medical degree from the University of Ulm in Germany, and a Master of Business Administration from Schiller University in France.
NOD-Proteindesign.Andreas Heddergott/TUM.jpg
Certest
Consilium